نمایش پرونده ساده آیتم

dc.contributor.authorJafarizad, A
dc.contributor.authorTaghizadehgh-Alehjougi, A
dc.contributor.authorEskandani, M
dc.contributor.authorHatamzadeh, M
dc.contributor.authorAbbasian, M
dc.contributor.authorMohammad-Rezaei, R
dc.contributor.authorMohammadzadeh, M
dc.contributor.authorTo?ar, B
dc.contributor.authorJaymand, M
dc.date.accessioned2018-08-26T09:31:46Z
dc.date.available2018-08-26T09:31:46Z
dc.date.issued2018
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/57163
dc.description.abstractThis paper describes the development of mitoxantrone-loaded PEGylated graphene oxide/magnetite nanoparticles (PEG-GO/Fe3O4-MTX), and investigation of its preliminary drug delivery performance. For this, the GO was synthesized through oxidizing graphite powder, and subsequently carboxylated using a substitution nucleophilic reaction. The carboxylated GO (GO-COOH) was then conjugated with amine end-caped PEG chains by Steglich esterification. Afterward, GO-PEG/Fe3O4 nanocomposite was synthesized through the anchoring of Fe3O4 nanoparticles onto the surface of GO-PEG during the sonication. The biocompatibility and MTX-loading capacity of the synthesized GO-PEG/Fe3O4 nanocomposite were evaluated. The pH dependent drug release behavior and cytotoxicity effect of the MTX-loaded GO-PEG/Fe3O4 nanocomposite were also studied. According to biocompatibility, pH dependent drug release behavior as well as superior physicochemical and biological characteristics of graphene and magnetite nanoparticles, it is expected that the GO-PEG/Fe3O4 nanocomposite may be applied as de novo drug delivery system (DDS) for cancer therapy using both chemo-and photothermal therapy approaches. © 2018 -IOS Press and the authors. All rights reserved.
dc.language.isoEnglish
dc.relation.ispartofBio-Medical Materials and Engineering
dc.subjectBiocompatibility
dc.subjectChemotherapy
dc.subjectControlled drug delivery
dc.subjectDiseases
dc.subjectGraphene
dc.subjectGraphene oxide
dc.subjectMagnetite
dc.subjectMagnetite nanoparticles
dc.subjectNanocomposites
dc.subjectNanoparticles
dc.subjectNanosystems
dc.subjectSynthesis (chemical)
dc.subjectTargeted drug delivery
dc.subjectBiological characteristic
dc.subjectCancer Chemotherapy
dc.subjectCytotoxicity effects
dc.subjectDrug delivery system
dc.subjectMitoxantrone
dc.subjectNucleophilic reaction
dc.subjectPhotothermal therapy
dc.subjectSteglich esterifications
dc.subjectDrug delivery
dc.subjectamine
dc.subjectchloroacetic acid
dc.subjectdicyclohexylcarbodiimide
dc.subjectgraphene
dc.subjectgraphene oxide
dc.subjecthydroxyl group
dc.subjectiron nanoparticle
dc.subjectmacrogol
dc.subjectmagnetite nanoparticle
dc.subjectmitoxantrone
dc.subjectn hydroxysuccinimide
dc.subjectArticle
dc.subjectbiocompatibility
dc.subjectcancer chemotherapy
dc.subjectcancer therapy
dc.subjectcarboxylation
dc.subjectcatalyst
dc.subjectchemical analysis
dc.subjectchemical interaction
dc.subjectchemical reaction
dc.subjectclinical evaluation
dc.subjectcytotoxicity
dc.subjectdrug conjugation
dc.subjectdrug delivery system
dc.subjectdrug effect
dc.subjectdrug release
dc.subjectdrug synthesis
dc.subjectesterification
dc.subjecthydrogen bond
dc.subjectnanoencapsulation
dc.subjectnucleophilicity
dc.subjectpH
dc.subjectphotothermal therapy
dc.subjectphysical chemistry
dc.subjectpowder
dc.subjectpriority journal
dc.subjectreaction analysis
dc.subjectsurface area
dc.subjectultrasound
dc.titlePEGylated graphene oxide/Fe3O4site: Synthesis, characterization, and evaluation of its performance as de novo drug delivery nanosystem
dc.typeArticle
dc.citation.volume29
dc.citation.issue2
dc.citation.spage177
dc.citation.epage190
dc.citation.indexScopus
dc.identifier.DOIhttps://doi.org/10.3233/BME-171721


فایلهای درون آیتم

فایلهاسایزفرمتنمایش

هیچ فایل مرتبطی وجود ندارد

این آیتم در مجموعه های زیر مشاهده می شود

نمایش پرونده ساده آیتم